SecBot SecBot
6-K ·Filed Sep 14, 2026

AZN

ASTRAZENECA PLC
BEARISH
Impact 5/10
Horizondays Processed2mo ago SEC0001654954-26-008323
Notable filing: 6-K
Actionable Insight ▼ Bearish

Expect modest near-term pressure on AZN shares as the market prices in a narrower peak-sales opportunity for Etcamah in the 1st-line setting. Monitor upcoming data from the CAMBRIA-1 and CAMBRIA-2 adjuvant trials, which represent a larger patient population and could offset this setback. The SERENA-6 label for ESR1-mutant patients provides a commercial floor.

DirectionBearish
Confidencehigh
Horizondays

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+20
Entry
$163.78
T+0 close · Sep 14, 2026 · via day close
Latest settled
−3.33%
T+20 · $158.33 · next T+60 in 22d
Vs SPY
−5.59%
α at T+20
Latest observation
+14.15%
T+44 · FF3 residual α
  1. T+0 · Sep 14 $163.78entry
  2. T+1 · 2mo ago −1.18%α −0.72% · $161.85
  3. T+5 · 8w ago +2.64%α +2.53% · $168.10
  4. T+20 · 5w ago −3.33%α −5.59% · $158.33
  5. T+45 · todayOpen
  6. T+60 · in 22d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

AstraZeneca announced that the Phase III SERENA-4 trial of Etcamah (camizestrant) plus palbociclib in 1st-line advanced ER+/HER2- breast cancer did not meet its primary endpoint of statistically significant improvement in progression-free survival, though a numerical improvement was observed. This is a negative read for the Etcamah franchise's potential in the broader 1st-line setting, but Etcamah remains approved in the US/EU/Japan for ESR1-mutant patients based on the SERENA-6 trial, and the ongoing CAMBRIA-1/2 adjuvant trials (approx. 10,000 patients) provide a separate long-term opportunity. The stock impact is likely modest given AZN's diversified pipeline and the fact that the SERENA-6 label already covers the key ESR1-mutant indication.

Key Facts

  • SERENA-4 Phase III trial of Etcamah + palbociclib did not meet primary endpoint of statistically significant PFS improvement in 1st-line advanced ER+/HER2- breast cancer.
  • A numerical improvement in PFS was observed, but the trial failed to show statistical significance versus anastrozole + palbociclib.
  • Etcamah remains approved in the US, EU, Japan, and other countries for ESR1-mutant advanced breast cancer based on the SERENA-6 trial.
  • The CAMBRIA-1 and CAMBRIA-2 Phase III adjuvant trials (approx. 10,000 patients) are ongoing and represent the broader early-breast-cancer opportunity.
  • No new safety concerns were identified; safety profile consistent with known profiles of each medicine.
  • The trial enrolled 1,371 adult patients with Stage IV de novo or recurrent disease who had not received prior systemic treatment for metastatic disease.

Financial Impact

Negative read for Etcamah's 1st-line label expansion potential; Etcamah is already approved for ESR1-mutant patients (SERENA-6 label). The failed SERENA-4 trial reduces the probability of broadening the label to the all-comers 1st-line population, which could have been a multi-billion-dollar peak-sales opportunity. However, the SERENA-6 label and adjuvant CAMBRIA trials remain intact.

revenuepipeline value

Risk Factors

  • Further negative read-through to the broader Etcamah development program if adjuvant trials also fail.
  • Competitive pressure from other oral SERDs (e.g., elacestrant) and CDK4/6 inhibitor combinations in the 1st-line setting.
  • Potential for delayed or reduced peak sales estimates for Etcamah, impacting AZN's long-term oncology revenue growth.

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
80% bullish (35 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001654954-26-008323
Document: 0001654954-26-008323-index-headers.html0001654954-26-008323
Document: 0001654954-26-008323-index.html0001654954-26-008323
Document: 0001654954-26-008323.txt0001654954-26-008323

Track record

77 reports on AZN

Performance horizon

19 of 37 bullish or bearish reports moved the stock their way by T+5. Best: +20.72% at T+60 after the Aug 17, 2026 report. 28 of 37 went positive at some point.

Filters
  1. Nov 16, 2026today 6-K Bullish 6/10 Entry price pending
  2. Nov 16, 2026today 6-K Bullish 6/10 Entry $185.55 Now $184.02 −0.82% settles Nov 23
  3. Nov 16, 2026today 6-K Bullish 6/10 Entry $185.31 Now $184.02 −0.70% settles Nov 23
  4. Nov 16, 2026today 6-K Bullish 5/10 Entry $185.09 Now $184.02 −0.58% settles Nov 23
  5. Nov 4, 202611d ago Institutional Cluster Mixed 3/10 Entry $186.85 to $184.38 Now $184.02 −1.51% ▼ −1.32% −4.61% vs SPY
  6. Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.02 −1.37% ▲ +1.51% +1.43% vs SPY
  7. Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.02 −1.37% ▲ +1.51% +1.43% vs SPY
  8. Oct 30, 202617d ago 6-K Neutral 5/10 Entry $186.65 to $186.43 Now $184.02 −1.41% ▼ −0.12% +2.59% vs SPY
  9. Oct 27, 202620d ago 6-K Bullish 5/10 Entry $170.08 to $183.88 Now $184.02 +8.20% ▲ +8.11% +10.10% vs SPY
  10. Oct 22, 202625d ago 6-K Bullish 6/10 Entry $172.57 to $173.46 Now $184.02 +6.63% ▲ +0.51% −0.19% vs SPY
Showing 10 of 77

US Market Status

Market Closed · Opens Tue (16h 43m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 14, 2026